In costing study | Not in costing study | |||
---|---|---|---|---|
C group(n = 98) | NoC group(n = 96) | C group(n = 266) | NoC group(n = 265) | |
C, chemotherapy + supportive care; NoC, supportive care only; CV, cisplatin + vindesine; MIC, mitomycin, ifosfamide + cisplatin; MVP, mitomycin, vinblastine + cisplatin; NP, vinorelbine + cisplatin. | ||||
Age (years) | ||||
Range | 43–86 | 36–87 | 42–81 | 40–84 |
Median | 65 | 65 | 65 | 65 |
Sex | ||||
Male | 70 (71%) | 67 (70%) | 205 (77%) | 193 (73%) |
Female | 28 (29%) | 29 (30%) | 61 (23%) | 72 (27%) |
Performance status | ||||
0 | 21 (21%) | 23 (24%) | 58 (22%) | 65 (25%) |
1 | 55 (56%) | 47 (49%) | 150 (56%) | 144 (54%) |
2 | 21 (21%) | 25 (26%) | 51 (19%) | 50 (19%) |
3 | 1 (1%) | 1 (1%) | 7 (3%) | 6 (2%) |
Chemotherapy regimen | ||||
CV | 8 (8%) | 9 (9%) | 8 (3%) | 9 (3%) |
MIC | 45 (46%) | 38 (40%) | 82 (31%) | 83 (31%) |
MVP | 32 (33%) | 31 (32%) | 121 (45%) | 120 (45%) |
NP | 13 (13%) | 18 (19%) | 55 (21%) | 53 (20%) |
Histology | ||||
Squamous | 49 (50%) | 53 (55%) | 145 (55%) | 132 (50%) |
Adenocarcinoma | 30 (31%) | 23 (24%) | 50 (19%) | 66 (25%) |
Other NSCLC | 19 (19%) | 20 (21%) | 71 (27%) | 67 (25%) |
Stage | ||||
I | 1 (1%) | 3 (3%) | 5 (2%) | 3 (1%) |
II | 5 (5%) | 1 (1%) | 9 (3%) | 11 (4%) |
IIIa | 18 (18%) | 20 (21%) | 49 (18%) | 67 (25%) |
IIIb | 39 (40%) | 32 (33%) | 96 (36%) | 79 (30%) |
IV | 34 (35%) | 38 (40%) | 102 (38%) | 98 (37%) |
Uncertain | 1 (1%) | 2 (2%) | 5 (2%) | 7 (3%) |